Morgan Stanley
PCSA icon

Morgan Stanley’s Processa Pharmaceuticals PCSA Stock Holding History

Morgan Stanley’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-98
Closed -$111K – 7944
2022
Q3 		$111K Hold
98
– – ﹤0.01% 6022
2022
Q2 		$138K Buy
+98
New +$134K ﹤0.01% 6100
2022
Q1 		– Hold
0
– – – 8076
2021
Q4 		– Hold
0
– -$1K – 8072
2021
Q3 		– Hold
0
– – – 7792
2021
Q2 		– Hold
0
– -$1K – 7783
2021
Q1 		– Hold
0
– – – 7364

Other funds holding PCSA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley's PCSA Position: Q4 2022 in Review

Morgan Stanley sold out of Processa Pharmaceuticals (PCSA) in Q4 2022, closing a stake of 98 shares — an estimated $111K sold.

Morgan Stanley first reported a position in PCSA in Q2 2022 and held it in 2 quarters. The position peaked at $138K in Q2 2022. 17 funds tracked by Wall St. Rank hold PCSA as of Q4 2022.

  • Morgan Stanley reported no remaining Processa Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Morgan Stanley sold 98 Processa Pharmaceuticals shares in Q4 2022, an estimated $111K.
  • Morgan Stanley first reported a position in Processa Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Morgan Stanley's Processa Pharmaceuticals position peaked at $138K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.